Real patient, real story
“I don't think of my Alzheimer’s every day”
Real patient, real story
“I don't think of my Alzheimer’s every day”
Kisunla gave this real patient a glimmer of hope for the future
Pat knows how uncertain the future feels when you've been diagnosed with early symptomatic Alzheimer’s disease (AD). As an avid traveler who loves spending time with her family and friends, she wants to keep doing the things she loves most as long as possible. Discover how treatment with Kisunla gave her hope.
Why Kisunla?
Kisunla is a treatment for early symptomatic AD and in clinical studies showed a 22% slowing of decline versus placebo. Kisunla was studied in an 18-month clinical study versus placebo. Kisunla does not reverse or cure AD.
Pat’s story
00:00 – 00:06
Caption: Please see the Indication and Select Safety Information before Pat’s story.
00:07 – 00:18
Narrator: INDICATION. Kisunla is for adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
00:20 – 00:47
Narrator: SELECT SAFETY INFORMATION. Kisunla can cause Amyloid Related Imaging Abnormalities, or “ARIA.” ARIA is a common but serious side effect that does not usually cause any symptoms, but can be serious. ARIA can be fatal. ARIA is most commonly seen as temporary swelling in an area or areas of the brain that usually goes away over time. Some people may also have spots of bleeding on the surface of or in the brain and infrequently, larger areas of bleeding in the brain can occur.
00:47 – 01:16
Narrator: Although most people do not have symptoms, some people have headache, dizziness, nausea, difficulty walking, confusion, vision changes, and seizures. Call your healthcare provider or go to the emergency room right away if you have any of these symptoms. You should carry information that you are receiving Kisunla, which can cause ARIA, and that ARIA symptoms can look like stroke symptoms.
Your healthcare provider will do magnetic resonance imaging (MRI) brain scans before and during your treatment with Kisunla to check you for ARIA.
01:17 – 01:22
Narrator: See Indication and Safety Summary with Warnings at the end of this video.
01:24 – 01:48
Song: Piano melody plays softly
Pat: Oh, I love to travel! I love to learn about different cultures, countries. Learn the customs of that place. I realized years ago that I was having some memory issues. I would walk into a room, and I could not remember why I went there.
01:49 – 01:05
Pat: When I first heard that I do have Alzheimer's, of course I started to cry.
Caption: Pat is living with early symptomatic Alzheimer’s disease, and was compensated for her time.
01:56 – 02:01
Pat: I was thinking “Oh, five years down the road I'm not going to remember my grandchildren's names”.
02:02 – 02:05
Pat: I didn't think I'd forget Rafik’s name (laugh).
Caption: Rafik– Pat’s Husband
02:12 – 02:22
Caption: Claudine, Michelle, Janine– Pat’s Daughters
Janine: When mom got her diagnosis…we knew, I knew, it’s just kind of maintaining symptoms as much as possible, and it’s a really heavy diagnosis.
Caption: Rafik, Michelle, and Janine were compensated for their time.
02:23 – 02:30
Claudine: At first, I think we were scared of the diagnosis and unsure. So many people feel shame related to it.
02:31 – 02:45
Song: Opening notes of "Here Comes the Sun" start to play
Pat: Well, when I heard that there was this drug that was being tested. I was so excited, because I thought I have to try it. Once a month I would go there, and I would get the infusions.
02:46 – 02:50
Claudine: This has truly slowed the progression of this disease.
02:51 – 02:58
Pat: The drug that that I’ve been on, Kisunla, it’s helping me live a normal life.
Caption: Kisunla (donanemab-azbt) is for adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
02:59 – 03:05
Michelle: She’s still able to do so many things that she loves doing…even despite the memory and thinking issues.
Caption: After 18 months in a clinical study, people treated with Kisunla showed a 22% slowing of decline vs placebo. Kisunla does not reverse or cure Alzheimer’s disease.
03:06 – 03:16
Michelle: She hasn’t skipped a beat. She’s keeping up with all of us and her grandkids. Once a month, to get an infusion, like…has made a difference for her and our family.
03:18 – 03:30
Pat: You should not be ashamed of having Alzheimer's. With getting the early diagnosis and treatment, I continue to enjoy the things that I've enjoyed.
03:31 – 03:37
Rafik: Pat is still travelling and dancing and singing and also telling me what to do (laughs).
03:38 – 03:42
Janine: Treatments that are available, it's just amazing to me. There's hope now.
03:43 – 03:53
Pat: Just because you're having some memory issues…don't just think that it's nothing. Please go get tested; see a doctor. It is so important.
03:54 – 04:05
Song: Singer’s voice starts to harmonize “Here Comes the Sun”
Rafik: The Patricia of today is not the Pat of five years ago, or ten years ago, but today we can diagnose the illness, and we can treat the illness.
04:06 – 04:12
Pat: I'm still doing things I love to do, and being with family and friends is what's most important.
04:15 – 04:21
Song: Music continues to build
Pat: Oooooohhh!
Claudine: All the grandkids.
Pat: Yeah…
04:24 – 04:34
Pat: This is why I love to go on vacation—all of us—so we can have these pictures. I want to see them grow up.
04:37 – 04:50
Pat: I don't think of my Alzheimer's every day. I have other things in my life to do… and to enjoy my family and my friends, and I feel so blessed.
04:57 – 05:03
SONG: “Here comes the sun. Here comes the sun and I say.”
Pat: I'm just looking forward to the future. Because of the Kisunla.
05:07 – 06:07
Caption: Indication and Safety Summary with Warnings
Narrator: Kisunla™ (kih-SUHN-lah) is used to treat adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
Warnings - Kisunla can cause Amyloid-Related Imaging Abnormalities or “ARIA.” This is a common side effect that does not usually cause any symptoms, but serious symptoms can occur. ARIA can be fatal. ARIA is most commonly seen as temporary swelling in an area or areas of the brain that usually goes away over time. Some people may also have spots of bleeding on the surface of or in the brain and infrequently, larger areas of bleeding in the brain can occur. Although most people do not have symptoms, some people have:
- Headache
- Confusion
- Dizziness
- Vision changes
- Nausea
- Difficulty walking
- Seizures
Some people have a genetic risk factor (homozygous apolipoprotein E ε4 gene carriers) that may cause an increased risk for ARIA. Talk to your healthcare provider about testing to see if you have this risk factor.
06:08 – 06:21
Narrator: You may be at higher risk of developing bleeding in the brain if you take medicines to reduce blood clots from forming (antithrombotic medicines) while receiving Kisunla. Talk to your healthcare provider to see if you are on any medicines that increase this risk.
06:26 – 06:41
Narrator: Your healthcare provider will do magnetic resonance imaging (MRI) brain scans before and during your treatment with Kisunla to check you for ARIA. You should carry information that you are receiving Kisunla, which can cause ARIA, and that ARIA symptoms can look like stroke symptoms. Call your healthcare provider or go to the nearest hospital emergency room right away if you have any of the symptoms listed above.
There are registries that collect information on treatments for Alzheimer’s disease. Your healthcare provider can help you become enrolled in these registries.
07:00 – 07:21
Narrator: Warnings - Kisunla can cause serious allergic and infusion-related reactions. Do not receive Kisunla if you have serious allergic reactions to donanemab-azbt or any of the ingredients in Kisunla. Symptoms may include swelling of the face, lips, mouth, or eyelids, problems breathing, hives, chills, irritation of skin, nausea, vomiting, sweating, headache, or chest pain. You will be monitored for at least 30 minutes after you receive Kisunla for any reaction. Tell your healthcare provider right away if you have these symptoms or any reaction during or after a Kisunla infusion. Other common side effects
- Headache
07:36 – 07:41
Narrator: Tell your healthcare provider right away if you have any side effects. These are not all of the possible side effects of Kisunla. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.
07:51 – 08:20
Narrator: Before you receive Kisunla, tell your healthcare provider:
- About all medicines you take, including prescription and over-the-counter medicines, as well as vitamins and herbal supplements. Especially tell your healthcare provider if you have medicines to reduce blood clots from forming (antithrombotic medicines, including aspirin).
- About all of your medical conditions including if you are pregnant, breastfeeding, or plan to become pregnant or breastfeed. Kisunla has not been studied in people who were pregnant or breastfeeding. It is not known if Kisunla could harm your unborn or breastfeeding baby.
08:24 – 08:40
Narrator: How to receive Kisunla
Kisunla is a prescription medicine given through an intravenous (IV) infusion using a needle inserted into a vein in your arm. Kisunla is given once every 4 weeks. Each infusion will last about 30 minutes.
08:41 – 08:52
Narrator: Learn more. For more information about Kisunla, call 1-800-LillyRx (1-800-545-5979) or go to kisunla.lilly.com.
08:53 – 09:15
Narrator: This summary provides basic information about Kisunla, it does not include all information known about this medicine. Read the information given to you about Kisunla. This summary provides basic information about Kisunla. It does not include all information known about this medicine. Read the information given to you about Kisunla. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Kisunla. Your healthcare provider is the best person to help you decide if Kisunla is right for you.
09:15 – 09:22
Narrator: Kisunla™ is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
Caption: DN CON BS APP
09:23 – 09:30
Narrator: Voice over audio created using AI.
Song: “Here comes the sun. Sun, sun, sun…Here it comes”
I have other things in my life to do, like enjoy my family and my friends. I feel so blessed.
PatAvid traveler and real patient
Have a Kisunla story of your own? Sharing your story could inspire others.
Receive emails on all things Kisunla to help you navigate early symptomatic AD with support
How does Kisunla help?